New haemophilia guidelines emphasise outcomes with newer agents

Game-changing new treatments such as emicizumab feature heavily in the new and expanded World Haemophilia Federation (WHF) guidelines for the management of haemophilia. For example, the 3rd edition of the WHF guidelines recommends prophylaxis with emicizumab to prevent haemarthrosis, spontaneous, and breakthrough bleeding in patients with severe phenotype haemophilia A without inhibitors. However the recommendations ...

Already a member?

Login to keep reading.

© 2021 the limbic